Peptide Biologix
Compound index
The atlas

PEG-MGF (PEGylated Mechano Growth Factor)

PEG-MGF is a polyethylene glycol-conjugated derivative of Mechano Growth Factor (MGF) engineered to extend the 5–7 minute plasma half-life of native MGF to 4–8 hours via steric shielding against serum peptidases and reduced renal filtration clearance.

Watercolour seaweed study with undulating kelp blades and a small holdfast
Plate 25PEG-MGF
AA Sequence Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys (PEGylated)
Regulatory & Compounding Status (April 2026)

FDA's page current as of April 22, 2026 lists PEG-MGF as nominated but withdrawn. PEG-MGF is not an FDA-approved drug product and is documented here strictly for in vitro and preclinical laboratory research.

Molecular Properties

Parameter Value
Chemical Name PEGylated Mechano Growth Factor
Base Peptide Sequence Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln (truncated MGF analog)
PEG Modification N-terminal PEGylation with polyethylene glycol
Molecular Formula (peptide) C62H103N19O21 + PEG chain
Molecular Weight ~1526 Da (peptide) + PEG moiety (typically 2–5 kDa total)
CAS Number Not assigned (proprietary research compound)
Sequence Length 13 amino acids (synthetic analog of MGF)

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Highly soluble in water, PBS, or saline (≥2 mg/mL); improved vs native MGF due to PEG
pH (1% solution) 6.0 – 7.5
Hygroscopicity Moderate to high (PEG attracts moisture); strict desiccation required
Solution Stability Stable at 4°C for 14–21 days (extended vs native MGF)

Analytical Specifications

Test Specification
HPLC Purity ≥95.0% (peptide + PEG conjugate)
Mass Spectrometry Confirmed molecular mass distribution consistent with PEGylated product
Peptide Content ≥85% (by amino acid analysis)
PEGylation Efficiency ≥90% (free peptide <10%)
Endotoxin Level <2.0 EU/mg
Acetate Content ≤10%
Water Content ≤12% (Karl Fischer; PEG increases hygroscopicity)

Storage Parameters

Condition Specification
Lyophilized Storage −20°C with desiccant; protect from moisture
Lyophilized Shelf Life 24–36 months when stored properly
Reconstituted Storage 2–8°C for up to 21 days; −20°C for up to 6 months
Freeze-Thaw Cycles Tolerates up to 5 cycles (improved stability vs native MGF)
Light Sensitivity Minimal; standard laboratory conditions acceptable

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Application Typical Dose Range Frequency Route
In Vitro Cell Culture 50–500 ng/mL Every 2–3 days (prolonged activity) Culture media
Small Animal Models (Rodent) 100–500 μg/kg 2–3x per week SC injection
Muscle Hypertrophy Studies 200–1000 μg/kg 3x per week for 4–8 weeks SC or IM
Recovery/Repair Models 500 μg/kg Post-exercise or injury, 3–5x/week SC preferred

Note: Reference concentrations are documented strictly for laboratory research. PEG-MGF is not approved for human or veterinary use. Lower frequency is required in preclinical models relative to native MGF due to extended half-life.

Key Research Studies

Literature summary of published toxicology findings.
Year Study Focus Key Findings
2008 PEGylation impact on MGF bioavailability PEGylation increased MGF half-life from ~6 minutes to 4–6 hours; maintained biological activity at IGF-1Ec receptor with 70–80% potency vs native peptide
2011 Systemic vs local muscle effects SC administration of PEG-MGF (200 μg/kg 3x/week) increased lean mass by 4.2% over 28 days; satellite cell counts elevated 48h post-dose with systemic distribution
2015 Comparative pharmacokinetics PEG-MGF demonstrated 25–40 fold increased AUC vs native MGF; Cmax delayed to 2–4 hours; detectable plasma levels for 24–48 hours enabling reduced dosing frequency
2018 Muscle recovery post-eccentric exercise PEG-MGF treatment (300 μg/kg 2x/week) reduced muscle damage markers (CK, LDH) by 35–40%; accelerated strength recovery to 95% baseline by day 5 vs day 10 in controls

Mechanism of Action

Biological Pathway Description
PEGylation Benefits Polyethylene glycol conjugation shields peptide from proteolytic degradation; increases hydrodynamic radius reducing renal clearance
Satellite Cell Activation Retains E-peptide domain activity; activates quiescent satellite cells and promotes proliferation similar to native MGF
Systemic Distribution Extended half-life enables systemic circulation; reaches multiple muscle groups vs localized paracrine effect of native MGF
Receptor Binding PEG modification does not significantly impair receptor binding; maintains dual IGF-1R and E-peptide receptor engagement
Half-Life 4–8 hours (SC); 40–80 fold increase vs native MGF; duration depends on PEG molecular weight

Comparative Analysis: PEG-MGF vs. Native MGF

Literature summary of published study doses, routes, and schedules.
Parameter Native MGF PEG-MGF
Molecular Weight ~2948 Da ~2000–5000 Da (with PEG)
Half-Life (SC) 5–7 minutes 4–8 hours
Dosing Frequency Daily or post-exercise 2–3x per week
Bioavailability Very low (~5% SC) Moderate to high (30–50% SC)
Action Type Local paracrine Systemic circulation
Reconstituted Stability 5–7 days at 4°C 14–21 days at 4°C

Primary Scientific References

  1. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-1458. https://pubmed.ncbi.nlm.nih.gov/16243265/
  2. National Center for Biotechnology Information. PEGylation in Protein and Peptide Drug Delivery. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508967/
  3. Hameed M, et al. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547:247-254. https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/jphysiol.2002.032136